Exploring novel therapeutic targets in GIST: Focus on the PI3K/Akt/mTOR pathway

Current Oncology Reports

Volumn 15, Issue 4, 2013, Pages 386-395

  Patel, Shreyaskumar ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Akt; GIST; Imatinib; Inhibitor; KIT; mTOR; PDGFRA; PI3K; RTK; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; APITOLISIB; BUPARLISIB; EVEROLIMUS; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; RAPAMYCIN; RIDAFOROLIMUS; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; TUMOR SUPPRESSOR PROTEIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE DELETION; GENE MUTATION; GENE SILENCING; HUMAN; HYPOKALEMIA; IN VIVO STUDY; INTENTION TO TREAT ANALYSIS; INTRACELLULAR SIGNALING; KIT GENE; LYMPHOCYTOPENIA; MONOTHERAPY; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PDGFRA GENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIK3R1 GENE; PIK3R2 GENE; PIK3R3 GENE; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATOR GENE; SARCOMA; SOLID TUMOR; STRUCTURAL HOMOLOGY; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84880803129     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0316-6     Document Type: Article

References (68)

1. Ducimetiere F, Lurkin A, Ranchere-Vince D, et al. Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhone-Alpes region. Bull Cancer. 2010;97:629-41.
2. Schoffski P, Reichardt P, Blay JY, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010;21:1990-8.
3. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006;17 Suppl 10:x280-6. (Pubitemid 44542023)
4. Cichoz-Lach H, Kasztelan-Szczerbinska B, Slomka M. Gastrointestinal stromal tumors: epidemiology, clinical picture, diagnosis, prognosis and treatment. Pol Arch Med Wewn. 2008;118:216-21. (Pubitemid 351613062)
5. Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol. 1999;23:377-89. (Pubitemid 29159998)
6. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33:459-65. (Pubitemid 34747864)
7. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097-104.
8. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-80. (Pubitemid 28067289)
9. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125:660-7. (Pubitemid 37070684)
10. Sommer G, Agosti V, Ehlers I, et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA. 2003;100:6706-11. (Pubitemid 36666644)
11. Maleddu A, Pantaleo MA, Nannini M, Biasco G. The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting. J Transl Med. 2011;9:75.
12. Cohen MH, Farrell A, Justice R, Pazdur R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Oncologist. 2009;14:174-80.
13. Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol. 2000;18:3211-20.
14. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244:176-84. (Pubitemid 44305531)
15. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res. 2009;15:7510-8.
16. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13:1367-73. (Pubitemid 46450424)
17. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-38. (Pubitemid 44528723)
18. Leigl B, Fletcher JA, Corless CL, et al. Correlation between KIT mutations and sunitinib (SU) resistance in GIST [abstract 92]. Presented at the 2008 ASCO Gastrointestinal Cancers Symposium. Orlando, Florida, USA; January 25-27, 2008.
19. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80. (Pubitemid 34879334)
20. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-34. (Pubitemid 39296599)
21. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24:4764-74. (Pubitemid 46630941)
22. •• Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology Nat Rev Cancer. 2011;11:865-78. A comprehensive review of GIST focusing on pathologic characteristics, oncogenic mutations, and mechanisms of resistance.
23. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128:270-9. (Pubitemid 40431080)
24. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182-90. (Pubitemid 40791584)
25. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004;64:5913-9. (Pubitemid 39129383)
26. Lim KH, Huang MJ, Chen LT, et al. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Med Oncol. 2008;25:207-13.
27. Ou WB, Fletcher CDM, Demetri GD, Fletcher JA. Protein kinase C theta (PKCθ) and c-Jun regulate proliferation through cyclin D1 in KIT-independent gastrointestinal stromal tumors [abstract 952]. Presented at the 102nd Annual Meeting of the AACR. Orlando, Florida, USA; April 2-6, 2011.
28. Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA. 2008;105:8387-92. (Pubitemid 351904765)
29. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620-5. (Pubitemid 351264357)
30. Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene. 2007;26:7560-8. (Pubitemid 350207707)
31. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11:289-301.
32. Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615-75. (Pubitemid 33096187)
33. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998;67:481-507. (Pubitemid 28411136)
34. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550-62.
35. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008;27:5486-96.
36. Mahalingam D, Mita A, Sankhala K, et al. Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets. 2009;10:937-49.
37. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem. 1998;273:13375-8. (Pubitemid 28268370)
38. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627-44.
39. Sridharan S, Basu A. S6 kinase 2 promotes breast cancer cell survival via Akt. Cancer Res. 2011;71:2590-9.
40. Pastor MD, Garcia-Yebenes I, Fradejas N, et al. mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. J Biol Chem. 2009;284:22067-78.
41. Glantschnig H, Fisher JE, Wesolowski G, et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003;10:1165-77. (Pubitemid 37258582)
42. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010;1804:433-9.
43. •• Rios-Moreno MJ, Jaramillo S, Diaz-Delgado M, et al. Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res. 2011;31:3019-25. Characterizes genetic alterations of the PI3K and MAPK pathways in primary wild-type and mutated GIST samples.
44. Sapi Z, Fule T, Hajdu M, et al. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. Diagn Mol Pathol. 2011;20:22-33.
45. Steelman LS, Chappell WH, Abrams SL, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging Aging (Albany NY). 2011;3:192-222.
46. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-10. (Pubitemid 36159485)
47. Daniels M, Lurkin I, Pauli R, et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett. 2011;312:43-54.
48. Quattrone A, Wozniak A, Dewaele B, et al. PTEN inactivation in gastrointestinal stromal tumors (GIST): possible relevance for treatment of imatinib-resistant disease. Mol Cancer Ther. 2011;10:A166. abstract.
49. •• Wang CM, Huang K, Zhou Y, et al. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. J Cancer Res Clin Oncol. 2010;136:1065-71. Assesses the molecular and genomic changes in imatinib-resistant GISTs, providing rationale for targeting the PI3K/Akt/mTOR pathway in this cancer type.
50. Ricci R, Maggiano N, Castri F, et al. Role of PTEN in gastrointestinal stromal tumor progression Arch Pathol Lab Med. 2004;128:421-5.
51. Yang J, Ikezoe T, Nishioka C, et al. Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. Int J Cancer. 2012;130:959-66.
52. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget. 2010;1:530-43.
53. Reichardt P, Reichardt A, Pink D. Molecular targeted therapy of gastrointestinal stromal tumors. Curr Cancer Drug Targets. 2011;11:688-97.
54. • Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28:1075-83. An in-depth review describing PI3K/Akt/mTOR pathway signaling, its role in multiple cellular processes, and potential inhibition in human cancers.
55. Conley AP, Araujo D, Ludwig J, et al. A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2009;27:10563. abstract.
56. Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003;2:1093-103.
57. Pantaleo MA, Nicoletti G, Nanni C, et al. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J Exp Clin Cancer Res. 2010;29:173.
58. Hohenberger P, Bauer S, Gruenwald V, et al. Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST. J Clin Oncol. 2010;28:10048. abstract.
59. Richter S, Pink D, Hohenberger P, et al. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. J Clin Oncol. 2010;28:10038. abstract.
60. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121:1231-41.
61. Li F, Growney J, Battalagine L, et al. The effect combining the KIT inhibitor imatinib with the PI3K inhibitor BKM120 or the dual PI3K/mTOR inhibitor BEZ235 on the proliferation of gastrointestinal stromal tumor cell lines [abstract 2239]. Presented at the 102nd Annual Meeting of the AACR. Chicago, Illinois, USA; March 31-April 4, 2012.
62. Floris G, Sciot R, Wozniak A, et al. Activity of GDC-0941, an inhibitor of phosphotidylinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib. J Clin Oncol. 2010;25:10020. abstract.
63. Van Looy T, Wozniak A, Sciot R, et al. Efficacy of a phosphoinositol 3 kinase (PI3K) inhibitor in gastrointestinal stromal tumor (GIST) models. J Clin Oncol. 2012;30:10030. abstract.
64. Chiorean EG, Mahadevan D, Harris WB, et al. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol. 2009;27:2558. abstract.
65. Wagner AJ, Bendell JC, Dolly S, et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol. 2011;29:3020. abstract.
66. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64-74.
67. Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA. 2009;106:1542-7.
68. Juric D, Baselga J. Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. J Clin Oncol. 2012;30:765-6.